Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
://www.CellTherapeutics.com/investors target _new http://www.CellTherapeutics.com/investors
Date:12/8/2008